TZ has been shown to have efficacy in treating HER2‐positive breast cancer as a monotherapy as well as when combined with chemotherapy (Slamon et al., 2001; Vogel et al., 2002; Vu and Claret, 2012). Here, ERBB2 is linked to breast carcinoma.